Preeti Srivastava, APRN
Psychiatric/Mental Health · Nashville, TNNPI 1043806516
Payments from drug & device makers
Across 724 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$829
- AbbVie$778
- Vanda Pharmaceuticals Inc.$727
- plus $5K from 17 others
What the payments were for
- Food & beverage$11,157100%
- Education$500%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 178 | $1,803 |
| Neurocrine Biosciences, Inc. | 55 | $1,157 |
| Alkermes, Inc. | 60 | $1,063 |
| Otsuka America Pharmaceutical, Inc. | 58 | $829 |
| AbbVie | 76 | $778 |
| Vanda Pharmaceuticals Inc. | 28 | $727 |
| Johnson & Johnson | 47 | $687 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $651 |
| Axsome Therapeutics, Inc. | 27 | $601 |
| E.r. Squibb & Sons, L.L.C. | 18 | $494 |
| Lundbeck LLC | 19 | $418 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $381 |
| Corium, LLC | 28 | $363 |
| Teva Pharmaceuticals USA, Inc. | 16 | $289 |
| Bausch Health US, LLC | 14 | $238 |
| Sunovion Pharmaceuticals Inc. | 12 | $233 |
| Noven Therapeutics, LLC | 7 | $126 |
| Ironshore Pharmaceuticals Inc. | 4 | $101 |
| Idorsia Pharmaceuticals US Inc | 5 | $98 |
| Neos Therapeutics, LP | 5 | $87 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| Indivior Inc. | 2 | $29 |
| Luye Pharma (USA) Ltd. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$251
How this compares
$11,207 in reported general payments places this provider in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 12 | $19,892 |
| RexultiBrexpiprazole | 12 | $18,691 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 91 | $7,394 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $5,080 |
| Bupropion XlBupropion Hcl | 88 | $3,623 |
| Duloxetine Hcl | 86 | $2,729 |
| Atomoxetine Hcl | 16 | $2,065 |
| Aripiprazole | 57 | $2,059 |
| Lisdexamfetamine Dimesylate | 12 | $1,751 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 35 | $1,690 |
| Trazodone Hcl | 59 | $1,657 |
| Divalproex Sodium ErDivalproex Sodium | 23 | $1,243 |
| Clomipramine Hcl | 17 | $1,127 |
| Lamotrigine | 72 | $882 |
| Buspirone Hcl | 25 | $732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $778 | $19,89212 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $829 | $18,69112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $381 | $5,08014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Nashville
- Kristian DambrinoNashville$449K
- Lauren HansenNashville$263K
- Aaron JonesNashville$20K
- Kathleen McCoyNashville$12K
- Kersten WoodleeNashville$10K
- Ariel NewtonNashville$10K
- Robert McKeownNashville$10K
- Debra YorkNashville$9K
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.